Hyponatremia is the most common electrolyte disorder, reported to occur in 15% to 22% of hospitalized pateints and affecting anywhere from 3 to 6 million patients in the United States each year.
A unique modality to help restore salt and water balance in hospitalized patients

Introducing Vaprisol®

VAPRISOL is a therapy for the management of euvolemic and hypervolemic hyponatremia in hospitalized patients. VAPRISOL is not indicated for treatment of patients with congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected clinical benefit of raising serum sodium outweighs the increased risk of adverse events for heart failure patients.

VAPRISOL offers a unique modality that blocks AVP

  • The neurohormone arginine vasopressin (AVP) plays a key role in salt and water balance—increased AVP levels trigger free water reabsorption in the kidneys3
  • Increased free water reabsorption results in increased blood volume with dilute sodium concentrations, which may lead to hyponatremia4
  • VAPRISOL has a high affinity for the V1A receptors in vascular smooth muscle and for the V2 receptors in the collecting ducts of the kidneys5,6
    • V1A receptors play a role in vascular smooth muscle tone5
    • V2 receptors regulate free water reabsorption5
  • VAPRISOL blocks the V2 receptors in the collecting ducts of the kidneys, resulting in aquaresis—the electrolyte-sparing excretion of free water6

You need Acrobat Reader to open PDFs. Download the free reader at Acrobat.com

VAPRISOL.COM is dedicated to keeping you informed of the latest developments about drug and treatment options for euvolemic and hypervolemic hyponatremia

FDA approves Astellas' VAPRISOL® (conivaptan HCl) for the treatment of hypervolemic hyponatremia

Read full story

Important Safety Information

  • VAPRISOL is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients
  • VAPRISOL is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events
  • VAPRISOL is contraindicated in patients with hypovolemic hyponatremia. In addition, coadministration of VAPRISOL with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritanovir, and indinavir, is contraindicated
  • Serum sodium, volume, and neurological status must be monitored frequently because VAPRISOL potentially can cause overly rapid correction of sodium leading to serious sequelae
  • The use of VAPRISOL in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering VAPRISOL to these patients
  • The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day, respectively) which were also the most common type of adverse reaction leading to discontinuation of VAPRISOL. Discontinuations from treatment due to infusion site reactions were more common among VAPRISOL-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for VAPRISOL 20 mg/day and 40 mg/day, respectively

References: 1. Douglas I. Hyponatremia: Why it matters, how it presents, how we can manage it. Cleve Clin J Med. 2006;73(3):S4-S12. 2. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Effectiveness and Resource Allocation. 2006;4:10. doi:10.1/186/1478-7547-4-10. 3. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17:471-503. 4. Goh KP. Management of hyponatremia. Am Fam Physician. 2004;69:2387-2394. 5. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res. 2001;51:391-402. 6. Vaprisol Prescribing Information. Astellas Pharma US, Inc.